Item Code

Package Insert

VALENINA®

13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Please read the package insert carefully and follow the physician's guidance to use.

1 PRODUCT NAME

Trade name: **VALENINA®**

Generic name: 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

2 PRODUCT DESCRIPTION

The 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13-TT) is formulated by compounding the capsular polysaccharide antigen of *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, individually conjugated to tetanus toxoid carrier protein. The individual polysaccharides are extracted from the cultures of *Streptococcus pneumoniae*, and purified through centrifugation, precipitation, and ultrafiltration. The polysaccharides are chemically activated and derivatized, and then conjugated to tetanus toxoid carrier protein to form the glycoconjugate, with aluminum phosphate as the adjuvant. The vaccine should be shaken well to obtain a homogeneous milky white suspension. During storage, a white deposit and clear supernatant might be observed due to adjuvant precipitation.

Active substances: capsular polysaccharides of *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F conjugated to tetanus toxoid carrier protein.

Excipients: sodium chloride, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate dodecahydrate, aluminum phosphate and water for injection.

3 INDICATION

The vaccine is indicated for use in infants and children 6 weeks through 5 years of age (before the 6th birthday).

Immune responses in recipients could be elicited by immunization of PCV13-TT, and this vaccine is indicated for the prevention of invasive diseases caused by 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) of *Streptococcus pneumoniae*.

The vaccine does not protect against diseases caused by *Streptococcus pneumoniae* serotypes that are not contained in the vaccine.

4 NAME AND STRENGTH OF ACTIVE SUBSTANCES

The vaccine is supplied as a single-dose of 0.5 mL/vial or 0.5 mL/pre-filled syringe with suspension for intramuscular injection. Each dose (0.5 mL) of the vaccine contains:

Pneumococcal polysaccharide serotype 1*	2.6 µg	Pneumococcal polysaccharide serotype 14*	2.75 µg
Pneumococcal polysaccharide serotype 3*	2.5 µg	Pneumococcal polysaccharide serotype 18C*	3.25 µg
Pneumococcal polysaccharide serotype 4*	3.0 µg	Pneumococcal polysaccharide serotype 19A*	2.6 µg
Pneumococcal polysaccharide serotype 5*	2.5 µg	Pneumococcal polysaccharide serotype 19F*	2.75 µg
Pneumococcal polysaccharide serotype 6A*	2.5 µg	Pneumococcal polysaccharide serotype 23F*	3.0 µg
Pneumococcal polysaccharide serotype 7F*	2.85 µg	Pneumococcal polysaccharide serotype 6B*	6.0 µg
Pneumococcal polysaccharide serotype 9V*	2.5 µg		

*conjugated to tetanus toxoid carrier protein, adsorbed on aluminium phosphate.

5 DOSAGE AND ADMINISTRATION

Since this product is a suspension containing an adjuvant, shake vigorously immediately prior to use to obtain a homogenous, white suspension in the vaccine container. This product is for intramuscular injection only. The preferred sites for injection are the anterolateral aspect of the mid-thigh in infants and the deltoid muscle of the upper arm in toddlers and children. The injection volume is 0.5 mL for each single human dose. The vaccine should not be injected in and/or near the areas where nerve trunks and/or blood vessels may locate.

Vaccination schedules for infants and toddlers

The product is to be administered as a four-dose series at 2, 4, 6, and 12-15 months of age or 3, 4, 5, and 12-15 months of age, respectively, as described in Table 1 and Table 2.

Table 1 Vaccination Schedule for Infants 2 Months of Age

Dose	Dose 1[a,b]	Dose 2[b]	Dose 3[b]	Dose 4[c]
Age at Dose	2 months	4 months	6 months	12-15 months

a Dose 1 may be given as early as 6 weeks of age.
b The recommended dosing interval is 8 weeks.
c The fourth dose should be administered at approximately 12-15 months of age.

Table 2 Vaccination Schedule for Infants 3 Months of Age

Dose	Dose 1[a]	Dose 2[a]	Dose 3[a]	Dose 4[b]
Age at Dose	3 months	4 months	5 months	12-15 months

a The recommended dosing interval is 4 weeks.
b The fourth dose should be administered at approximately 12-15 months of age.

For children 7 months through 5 years of age who have not received the product, the catch-up schedule in Table 3 applies:

Table 3 Vaccination Schedule for Infants and Toddlers 7 Months through 5 Years of Age

Age at First Dose	Total Number of 0.5 mL Doses
7-11 months of age	3[a]
12-23 months of age	2[b]
24 months through 5 years of age (prior to the 6th birthday)	1

a The first 2 doses at least 2 months apart; the third dose after the one-year birthday, separated from the second dose by at least 2 months.
b Two doses at least 2 months apart.

6 ADVERSE EVENTS

6.1 Clinical Trials for PCV13-TT

Two clinical trials (phase I and III) of PCV13-TT were conducted in China, including 120 and 2760 subjects, respectively; among all subjects (N=2880), 1754 had been vaccinated with at least one dose of PCV13-TT. The adverse events were observed through safety follow-up for all subjects, starting from the first dose through 7 days and 30 days post each dose for solicited and unsolicited adverse events, with long-term safety monitoring conducted until around 6 months after the last vaccination for serious adverse events (SAEs).

6.1.1 Summary

The incidence rates of adverse reactions reported in clinical trials, according to the guidance on classifications of adverse reactions recommended by The Council for International Organizations of Medical Sciences (CIOMS), are classified as: very common (≥ 10%), common (≥ 1% to < 10%), uncommon (≥ 0.1% to < 1%), rare (≥ 0.01% to < 0.1%) and very rare (< 0.01%). The safety data for the primary series of PCV13-TT collected from both phase I and phase III clinical trials of all subjects are summarized as follows:

Table 4 The Adverse Reactions Reported in Clinical Trials and Classified by CIOMS

	Systemic Adverse Reactions	Injection-site Adverse Reactions
Very Common (≥ 10%)	Fever Diarrhea	Redness
Common (≥ 1% to < 10%)	Crying Cough Nausea/vomiting Fatigue/somnolence Allergic reaction	Swelling Pain Induration
Uncommon (≥ 0.1% to < 1%)	Myalgia	Pruritus
Rare (≥ 0.01% to < 0.1%)	/	Rash

6.1.2 Adverse Reactions in Phase III Clinical Trial

6.1.2.1 Serious Adverse Events

SAEs were collected from Dose 1 till 180 days post complete series. In phase III, 1 case of SAE was reported during the primary series in the PCV13-TT (3 months of age) group (please refer to Table 2 for dosing regimen for subjects aged 3 months in PCV13-TT group). This SAE was reported to be fever and considered to be possibly related to PCV13-TT. Other SAEs were adjudicated to be irrelevant to PCV13-TT.

6.1.2.2 The Incidence Rates and Severity of Solicited Adverse Reactions

The incidence rates and severity of solicited adverse reactions post primary series and booster dose in phase III clinical trial of PCV13-TT comparing to the comparator vaccine (Pneumococcal 7-valent Conjugate Vaccine [Diphtheria CRM_{197} Protein], referred to as Prevenar®) are summarized in Table 5 and Table 6.

Table 5 Incidence Rates of Solicited Local Adverse Reactions in Phase III Clinical Trial in China

Symptoms and Grading of Local Adverse Reactions	3 Months PCV13-TT N*=488-519 %[b]	3 Months Prevenar® N*=493-519 %[b]	2[a] Months PCV13-TT N*= 487-517 %[b]	7-11 Months PCV13-TT N*=186-198 %[b]	7-11 Months Prevenar® N*=191-200 %[b]	12-23 Months PCV13-TT N*= 200 %	12-23 Months Prevenar® N*=200 %	24-71 Months PCV13-TT N*= 200 %	24-71 Months Prevenar® N*=200 %
Pain									
Any	0.20; 2.31	0.00; 1.93	0.21; 1.93	0.54; 7.07	0.52; 3.50	5.00	1.50	9.50	10.00
Grade 1[d]	0.20; 2.31	0.00; 1.93	0.21; 1.55	0.54; 6.57	0.52; 3.50	5.00	1.00	9.50	9.50
Grade 2[d]	0.00	0.00	0.00; 0.39	0.00; 0.51	0.00	0.00	0.50	0.00	0.50
Grade 3[d]	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redness									
Any	1.02; 10.60	0.61; 13.68	0.41; 7.93	0.54; 16.67	1.05; 12.50	8.00	7.00	9.50	8.00
Grade 1[c]	0.20; 6.74	0.20; 8.67	0.21; 5.42	0.00; 9.09	1.05; 11.50	4.50	3.50	4.50	5.00
Grade 2[c]	0.61; 3.08	0.41; 5.78	0.21; 2.32	0.54; 5.56	0.00; 1.00	1.50	2.50	3.00	1.50
Grade 3[c]	0.20; 1.16	0.00; 0.19	0.00; 0.19	0.00; 2.02	0.00	2.00	1.00	2.00	1.50
Swelling									
Any	0.82; 1.93	0.41; 3.47	0.62; 3.29	1.61; 7.58	1.05; 3.50	6.50	3.00	12.50	8.00
Grade 1[c]	0.20; 0.77	0.20; 2.31	0.62; 1.93	1.08; 1.52	1.05; 3.00	1.50	1.50	4.50	4.00
Grade 2[c]	0.41; 0.96	0.20; 1.16	0.00; 1.35	0.54; 4.55	0.00; 0.50	3.00	1.00	4.50	2.50
Grade 3[c]	0.20; 0.39	0.00; 0.19	0.00; 0.19	0.00; 1.52	0.00	2.00	0.50	3.50	1.50
Induration									
Any	0.20; 2.89	0.00; 3.47	0.00; 2.71	0.00; 3.03	0.00; 0.50	0.50	0.50	2.50	0.50
Grade 1[c]	0.00; 0.58	0.00; 1.73	0.00; 1.55	0.00; 1.52	0.00; 0.50	0.50	0.00	1.00	0.50
Grade 2[c]	0.20; 1.93	0.00; 1.35	0.00; 1.35	0.00; 0.51	0.00	0.00	0.50	1.50	0.00
Grade 3[c]	0.00; 0.58	0.00; 0.39	0.00	0.00; 1.01	0.00	0.00	0.00	0.00	0.00
Pruritus									
Any	0.00; 0.39	0.00; 0.39	0.00	0.00; 0.51	0.00; 0.50	1.00	0.00	5.00	1.00
Grade 1[e]	0.00; 0.39	0.00; 0.39	0.00	0.00; 0.51	0.00; 0.50	1.00	0.00	5.00	1.00
Grade 2[e]	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Grade 3[e]	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Rash (Injection Site)									
Any	0.00	0.00	0.00	0.00	0.00	0.50	0.00	0.00	0.00
Grade 1[c]	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Grade 2[c]	0.00	0.00	0.00	0.00	0.00	0.50	0.00	0.00	0.00
Grade 3[c]	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Any Local Reactions	1.64; 13.49	0.61; 15.61	1.03; 10.44	2.15; 21.21	2.09; 14.50	10.50	9.00	21.00	18.00
Grade 1	0.41; 8.48	0.20; 11.18	0.82; 7.54	1.61; 16.67	2.09; 13.50	9.50	5.50	17.00	15.00
Grade 2	1.23; 4.82	0.41; 6.17	0.21; 4.06	0.54; 8.59	0.00; 1.50	3.50	3.50	7.00	4.00
Grade 3	0.20; 1.54	0.00; 0.58	0.00; 0.39	0.00; 3.54	0.00	2.50	1.00	4.00	1.50

* N=number of subjects reporting "yes" for at least 1 day, or "no" for all 30 days.
a. Minimum age: 6 weeks.
b. The number on the left of ";" is the incidence rate of local adverse reactions observed after the booster dose, and that on the right of ";" is the incidence rate of local adverse reactions observed after primary immunization.
c. Grade 1, < 15 mm; grade 2, 15-30 mm; grade 3, > 30 mm.
d. Grade 1, not affecting activities; grade 2, affecting activities or multiple use of non-narcotic analgesics; grade 3, affecting daily activities or multiple use of narcotic analgesics.
e. Grade 1, mild itching in vaccination site; grade 2, moderate itching in limbs with vaccination; grade 3, systemic itching.

Table 6 Incidence Rates of Solicited Systemic Adverse Reactions in Phase III Clinical Trial in China

Symptoms and Grading of Systemic Adverse Reactions	3 Months PCV13-TT N*=488-519 %[b]	3 Months Prevenar® N*=493-519 %[b]	2[a] Months PCV13-TT N*=487-517 %[b]	7-11 Months PCV13-TT N*=186-198 %[b]	7-11 Months Prevenar® N*=191-200 %[b]	12-23 Months PCV13-TT N*= 200 %	12-23 Months Prevenar® N*=200 %	24-71 Months PCV13-TT N*=200 %	24-71 Months Prevenar® N*=200 %
Fever									
Any	28.07; 58.00	27.38; 66.28	21.56; 61.12	20.43; 53.54	20.94; 61.50	41.50	44.00	20.50	23.50
Grade 1[#]	17.01; 48.17	18.05; 57.61	15.40; 52.22	11.83; 35.86	13.09; 41.00	30.00	29.00	8.50	15.50
Grade 2[#]	10.86; 17.73	9.53; 22.35	6.78; 18.18	9.14; 23.23	7.85; 30.50	14.50	17.00	10.00	8.00
Grade 3[#]	1.23; 0.39	0.61; 0.39	0.00; 0.39	0.00; 3.03	0.00; 1.50	0.50	1.00	2.00	1.00
Grade 4[#]	0.00; 0.19	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fatigue / Somnolence									
Any	0.20; 6.17	0.20; 5.20	0.00; 3.09	0.00; 1.52	0.00; 2.50	1.00	1.00	2.50	1.50
Grade 1[c]	0.20; 5.01	0.20; 4.24	0.00; 2.71	0.00; 1.52	0.00; 2.00	0.50	0.50	2.50	1.50
Grade 2[c]	0.00; 1.73	0.00; 0.96	0.00; 0.39	0.00	0.00; 0.50	0.50	0.50	0.00	0.00
Grade 3[c]	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Nausea / Vomiting									
Any	1.64; 5.78	0.81; 3.66	0.21; 6.00	0.00; 5.56	1.05; 4.00	1.50	2.50	1.00	2.50
Grade 1[d]	0.82; 4.62	0.61; 2.31	0.21; 4.26	0.00; 4.55	1.05; 3.50	1.00	2.50	0.50	2.50
Grade 2[d]	0.61; 1.35	0.20; 1.54	0.00; 2.13	0.00; 1.52	0.00; 0.50	0.50	0.00	0.50	0.00
Grade 3[d]	0.20; 0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Diarrhea									
Any	2.46; 12.91	2.23; 11.95	0.41; 11.03	1.61; 7.07	1.05; 9.00	4.00	1.50	1.00	2.00
Grade 1[e]	1.23; 7.32	1.01; 6.17	0.21; 4.64	0.54; 4.55	0.00; 7.00	3.00	1.50	1.00	1.50
Grade 2[e]	1.23; 5.78	1.01; 6.17	0.21; 7.74	1.08; 2.53	1.05; 2.50	1.00	0.00	0.00	0.50
Grade 3[e]	0.00; 0.58	0.20; 0.19	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Myalgia									
Any	0.00; 0.19	0.00; 0.39	0.00; 0.19	0.00	0.00; 0.50	0.00	0.00	0.50	0.50
Grade 1[f]	0.00; 0.19	0.00; 0.39	0.00; 0.19	0.00	0.00; 0.50	0.00	0.00	0.50	0.50
Grade 2[f]	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Grade 3[f]	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cough									
Any	0.82; 7.32	1.22; 6.55	0.21; 5.61	0.54; 5.05	1.05; 4.50	5.00	5.50	4.00	5.50
Grade 1[g]	0.20; 5.01	0.61; 4.05	0.21; 4.64	0.00; 2.53	0.52; 2.50	1.00	2.00	3.00	2.00
Grade 2[g]	0.61; 2.31	0.61; 2.70	0.00; 0.77	0.54; 2.53	0.52; 2.00	4.00	3.50	1.00	3.00
Grade 3[g]	0.00	0.00; 0.19	0.00	0.00	0.00	0.00	0.00	0.00	0.50
Grade 4[g]	0.00	0.00	0.00; 0.19	0.00	0.00	0.00	0.00	0.00	0.00
Abnormal Crying									
Any	0.82; 10.40	0.61; 9.44	0.21; 10.44	1.08; 6.57	0.00; 6.00	2.50	1.50	0.00	1.50
Grade 1[h]	0.61; 6.94	0.20; 6.74	0.00; 6.77	0.00; 5.05	0.00; 4.50	0.50	0.50	0.00	1.00
Grade 2[h]	0.20; 3.85	0.20; 3.66	0.21; 4.64	1.08; 1.52	0.00; 1.50	2.00	1.00	0.00	0.50
Grade 3[h]	0.00; 0.19	0.20; 0.19	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Allergic Reaction									
Any	0.00; 0.58	0.00; 0.58	0.00; 0.58	0.00	0.52; 3.00	1.50	3.50	1.50	1.00
Grade 1[i]	0.00; 0.19	0.00; 0.19	0.00; 0.39	0.00	0.00; 0.50	0.50	1.50	0.00	0.00
Grade 2[i]	0.00; 0.19	0.00; 0.39	0.00	0.00	0.52; 1.00	0.50	1.00	1.50	0.50
Grade 3[i]	0.00; 0.19	0.00	0.00; 0.19	0.00	0.00; 1.50	0.50	1.00	0.00	0.50
Any Systemic Reactions[j]	30.33; 67.82	29.21; 71.48	22.38; 67.12	22.04; 58.59	22.51; 66.00	46.50	50.00	24.00	28.50
Grade 1	19.06; 57.61	19.27; 62.81	15.81; 57.64	12.37; 42.93	14.14; 49.00	33.50	34.00	13.00	19.50
Grade 2	12.91; 25.82	10.75; 30.83	7.19; 27.08	10.22; 27.27	9.42; 34.50	20.50	20.50	12.00	11.50
Grade 3	1.43; 1.35	0.81; 0.96	0.00; 0.58	0.00; 3.03	0.00; 3.00	1.00	2.00	2.00	2.00
Grade 4	0.00; 0.19	0.00	0.00; 0.19	0.00	0.00	0.00	0.00	0.00	0.00

* N=number of subjects reporting "yes" for at least 1 day, or "no" for all 30 days.
a. Minimum age: 6 weeks.
b. The number on the left of ";" is the incidence rate of systemic adverse reactions observed after the booster dose, and that on the right of ";" is the incidence rate of systemic adverse reactions observed after primary immunization.
\# Grade 1, 37.1-37.5 °C; grade 2, 37.6-39.0 °C; grade 3, > 39.0 °C.
c. Grade 1, slight reduction in normal activities for < 48 h, not affecting daily activities; grade 2, 20%-50% reduction in normal activities for > 48 h, affecting daily activities mildly; grade 3, > 50% reduction in normal activities, affecting daily activities severely and is unable to work.
d. Grade 1, once or twice/24 h, with basically normal intake and will not affect activities; grade 2, 2-5 times/24 h, with significantly reduced intake or restricted activities; grade 3, > 6 times/24 h, with no significant intake, and in need of intravenous infusion.
e. Grade 1, mild or transient with 2-3 times of loose stools/day, or mild diarrhea lasting < 1 week; grade 2, moderate or persistent diarrhea, 4-5 times/day, or diarrhea lasting > 1 week; grade 3, > 6 times of watery stool/day, or bloody diarrhea, orthostatic hypotension, electrolyte imbalance, in need of intravenous infusion of > 2 L.
f. Grade 1, not affecting daily activities; grade 2, tender muscles in non-vaccination sites, affecting daily activities mildly; grade 3, severe tender muscles, affecting daily activities severely.
g. Grade 1, transient, no treatment required; grade 2, persistent and controllable cough; grade 3, uncontrollable paroxysmal cough; grade 4, emergency care required.
h. Grade 1, slight increase in frequency than usual; grade 2, doubled frequency than usual; grade 3, doubled frequency than usual, and lasts > 3 days.
i. Grade 1, itching with no rash; grade 2, local urticaria; grade 3, extensive urticaria, angioedema.
j. All systemic reactions, including body temperature ≥ 37.1 °C, fatigue/somnolence, nausea/vomiting, diarrhea, myalgia, cough, abnormal crying, and allergic reactions.

6.1.2.3 Incidence Rates and Severity of Unsolicited Adverse Reactions

The incidence rates of unsolicited adverse reactions for PCV13-TT were 0.06%-0.73% with most episodes being grade 1 in severity. The documented symptoms include: nasal obstruction, rhinorrhea, nasopharyngitis, upper respiratory tract infection, oral ulcer, abdominal pain, abdominal distension, decreased appetite, hyperhidrosis, increased tearing and eye discharge and red eyelids.

7 CONTRAINDICATIONS

Hypersensitivity to any component of the product, including active substances, excipients, or tetanus toxoid, etc.

8 PRECAUTIONS

(1) Do not vaccinate via intravenous route or by gluteal intramuscular injection, and ensure the syringe needle is not puncturing blood vessels during injection.
(2) Check if the package, container, label, appearance and expiration date of the vaccine are in compliance with corresponding requirements before administration. Do not use the vaccine in case that any crack is observed in the container, loosened stopper, detached label, foreign particle(s) or discoloring inside the container, etc. Do not use the vaccine after the expiration date.
(3) During storage, a white deposit and clear supernatant can be observed. This does not constitute a sign of deterioration. The vaccine should be shaken well to obtain a homogenous white suspension prior to expelling air from the syringe, and should be inspected visually for any particulate matter and/or variation of physical aspect prior to administration. Do not use if the content appears otherwise.
(4) Use immediately after unsealing. A single human dose shall be used up each time according to prescribing information.
(5) The vaccination should be postponed in case of fever, acute diseases, and acute attack of chronic diseases.
(6) Appropriate monitoring and medical care and rescue measures should be readily available in case of occurrence of rare hypersensitivity reactions during vaccination. If allergic reactions occur after vaccination, please go to the vaccination site or hospital in time.
(7) Cautions should be taken for vaccination in recipients with thrombocytopenia, any coagulopathy or those who are receiving anticoagulant treatment.
(8) Preterm infants should be monitored for the potential risk of apnea during primary series.
(9) Valenina® in immune-compromised individuals (e.g., malignancy or nephrotic syndrome), vaccination in this special group should be considered on an individual basis.
(10) The use of PCV13-TT does not replace the use of 23-valent Pneumococcal Polysaccharide Vaccine in children ≥ 24 months of age with conditions such as sickle cell disease, asplenia, HIV infection, chronic illness, or those who are immuno-compromised.
(11) Under no circumstances shall the tetanus toxoid contained in the vaccine replace the routine immunization of tetanus vaccine or tetanus-containing vaccine.
(12) This product cannot guarantee all recipients can be protected from any diseases caused by *Streptococcus pneumoniae*.

9 PREGNANCY AND LACTATION

9.1 Pregnancy

No data are available for using the product in pregnant women.

9.2 Lactation

Whether this product is excreted into human milk remains unknown.

10 INTERACTIONS WITH OTHER MEDICAMENTS

No concomitant immunization data are available either inside or outside of China for the product.

During the phase III clinical trial of the product, the interval between vaccination of the product and any other diphtheria, tetanus, and acellular pertussis (DTaP)-containing vaccine was ≥ 10 days.

11 OVERDOSE AND TREATMENT

Overdose with PCV13-TT is unlikely due to its presentation as a single-dose vial or a single-dose pre-filled syringe. No overdose data are available for the product in recipients.

12 PHARMACODYNAMIC/PHARMACOKINETICS

Not applicable.

13 CLINICAL TRIALS

13.1 PCV13-TT Immunogenicity Clinical Trials in Healthy Subjects 2 through 71 Months of Age

In China, the pivotal phase III clinical trial of PCV13-TT was a randomized, blind and non-inferiority study comparing to Prevenar®. This study evaluated the immunogenicity and safety of PCV13-TT and Prevenar® in 2760 healthy subjects 2 through 71 months of age (at least 6 weeks of age). A total of 1040 infants aged 3 months were randomized in a 1:1 ratio as the PCV13-TT group and the Prevenar® group, with PCV13-TT or Prevenar® given at 3, 4, 5, and 12-15 months of age, respectively; for 520 infants aged 2 months (at least 6 weeks of age), PCV13-TT was vaccinated at 2, 4, 6 and 12-15 months of age. 1200 children of 7 through 71 months of age, including children 7 months through 11 months of age, 12 months through 23 months of age and 24 months through 5 years of age (prior to the 6th birthday) who were naïve to the pneumococcal conjugate vaccine, were split into three age groups with each containing 400 subjects randomized in a 1:1 ratio given 3, 2 or 1 dose of PCV13-TT or Prevenar®, respectively, according to the age-appropriate schedules in Table 1 to Table 3.

Immune responses elicited by PCV13-TT and Prevenar® were measured by serotype-specific IgG antibody concentration and the geometric mean concentration (GMC) of serotype-specific IgG antibody one month post primary series as primary endpoints. The IgG and GMC of IgG post booster dose, as well as serotype-specific OPA titer and OPA geometric mean titer (GMT) one month post primary series and booster dose as secondary endpoints.

For the 7 serotypes in common to both vaccines, non-inferiority between vaccines was met if the lower limit of the 2-sided 97.5% confidence interval (CI) of the positive rate difference (PCV13-TT minus the Prevenar®) was not less than -10%, or the lower limit of 2-sided 97.5% CI of the GMC ratio (PCV13-TT / Prevenar®) was not less than 0.5.

The response to the 6 additional serotypes, which is contained in PCV13-TT but not in Prevenar®, superiority between vaccines was met if the lower limit of 2-sided 95% CI of antibody positive rate was not less than 0, the lower limit of 2-sided 95% CI of the GMC ratio (PCV13-TT/Prevenar®) was not less than 1, and the lower limit of 2-sided 95% CI of IgG antibody positive rate was not less than 70%.

A subset of sera randomly obtained from 100 subjects in each age group for PCV13-TT and Prevenar®, totaling 900 subjects, were tested by opsonophagocytic assay (OPA) to measure the ability of serotype-specific functional antibodies to eliminate corresponding pneumococci by promoting complement-mediated phagocytosis.

For immunogenicity assessment, the immunogenicity results of PCV13-TT (2 months of age) group, Prevenar® (3 months of age) group and PCV13-TT (3 months of age) group were compared in sequence (please refer to Table 1 and Table 2 for dosing regimen for subjects in PCV13-TT (2 months of age) group and Prevenar® (3 months of age) group). The results are shown as below:

Main target population (3 months of age)

Primary series: In PCV13-TT (3 months of age) group, after primary series, six out of seven common serotypes met the non-inferiority criteria with the exception of 6B; the 6 additional serotypes reached superiority threshold; besides, the 6 additional serotypes in the PCV13-TT group were non-inferior to the serotype with the lowest response among all the 7 common serotypes in the Prevenar® group.

Booster dose: In PCV13-TT (3 months of age) group, after complete series, all 7 common serotypes met the non-inferiority criteria; the 6 additional serotypes reached superiority threshold; besides, the 6 additional serotypes in the PCV13-TT group were non-inferior to the serotype with the lowest response among all the 7 common serotypes in the Prevenar® group.

For PCV13-TT (2 months of age) group vs Prevenar® (3 months of age) group

Primary series: In PCV13-TT (2 months of age) group, after primary series, the IgG antibody was firstly compared between the PCV13-TT (2 months of age) group and the Prevenar® (3 months of age) group, showing that all 7 common serotypes met the non-inferiority criteria and the 6 additional serotypes reached superiority threshold; besides, the 6 additional serotypes in the PCV13-TT (2 months of age) group were non-inferior to the serotype with the lowest IgG response among all 7 common serotypes in the Prevenar® (3 months of age) group. The IgG antibody was then compared between the PCV13-TT (2 months of age) group and the PCV13-TT (3 months of age) group. IgG antibody of twelve out of the thirteen serotypes met the non-inferiority criteria with the exception of serotype 5.

Booster dose: In PCV13-TT (2 months of age) group, after complete series, the IgG antibody was firstly compared between the PCV13-TT (2 months of age) group and the Prevenar® (3 months of age) group. All 7 common serotypes met the non-inferiority criteria and the 6 additional serotypes reached superiority threshold; besides, the 6 additional serotypes in the PCV13-TT (2 months of age) group were non-inferior to the serotype with the lowest IgG response among all 7 common serotypes in the Prevenar® (3 months of age) group. The IgG antibody was then compared between the PCV13-TT (2 months of age) group and the PCV13-TT (3 months of age) group. IgG antibody of all the 13 serotypes met the non-inferiority criteria.

For PCV13-TT (7-11 months of age) group

Primary series: In PCV13-TT (7-11 months) group, after primary series, the proportions of subjects with IgG antibody concentration ≥ 0.35 µg/mL for common serotypes were all non-inferior to those in Prevenar® group. The additional serotypes in PCV13-TT (7-11 months of age) group of had reached superiority criteria after primary series.

Booster dose: In PCV13-TT (7-11 months of age) group, after complete series, all 7 common serotypes met the non-inferiority criteria and the 6 additional serotypes (except 19A) reached superiority threshold.

For PCV13-TT (12-23 months of age) group and PCV13-TT (24-71 months) group

Complete series: The proportions of subjects with IgG antibody concentration ≥ 0.35 µg/mL for common serotypes were all non-inferior to those in Prevenar® group. The additional serotypes in PCV13-TT (12-23 months) group and PCV13-TT (24-71 months of age) group, superiority criteria were generally met after primary series, except for serotype 19A in PCV13-TT (12-23 months of age) group and serotypes 6A and 19A in PCV13-TT (24-71 months of age) group.

Please refer to Table 3 for dosing regimen for subjects in PCV13-TT (7-11 months of age) group, PCV13-TT (12-23 months of age) group and PCV13-TT (24-71 months of age) group.

The testing results of OPA antibody demonstrated that all 13 serotypes of PCV13-TT were capable of inducing anti-pneumococcal OPA antibodies in all age groups in the PCV13-TT group.

The immunogenicity data from subjects 2 months (at least 6 weeks of age) through 71 months of age are shown in Table 7 to Table 12.

Table 7 Seroconversion Rates of IgG Antibody (Concentration ≥ 0.35 µg/mL) in Subjects Aged 2 Months and 3 Months following Immunizations (PPS)

Post Primary Series

Serotypes	3 Months PCV13-TT N=471 % (95%CI)	3 Months Prevenar® N=487 % (95%CI)	2 Months PCV13-TT N=482 % (95%CI)	% (CI*) PCV13-TT [3M#] – Prevenar® [3M#]	% (CI*) PCV13-TT [2M#] – Prevenar® [3M#]	% (CI*) PCV13-TT [2M#] – PCV13-TT [3M#]
Common						
4	100.0 (99.22-100.0)	99.18 (97.91-99.78)	100.0 (99.24-100.0)	0.82 (-0.10, 1.74)	0.82 (-0.10, 1.74)	0.00 (-0.93, 0.91)
6B	90.45 (87.42-92.95)	98.97 (97.62-99.67)	97.72 (95.95-98.86)	-8.53 (-11.73, -5.32)	-1.26 (-3.09, 0.58)	7.27 (3.87, 10.67)
9V	99.15 (97.84-99.77)	99.79 (98.86-99.99)	99.79 (98.85-99.99)	-0.64 (-1.70, 0.41)	-0.00 (-0.66, 0.65)	0.64 (-0.41, 1.70)
14	100.0 (99.22-100.0)	99.79 (98.86-99.99)	99.79 (98.85-99.99)	0.21 (-0.25, 0.67)	-0.00 (-0.66, 0.65)	-0.21 (-0.67, 0.26)
18C	98.30 (96.68-99.26)	97.74 (95.99-98.87)	98.96 (97.60-99.66)	0.56 (-1.45, 2.57)	1.22 (-0.61, 3.05)	0.66 (-1.03, 2.35)
19F	100.0 (99.22-100.0)	100.0 (99.25-100.0)	100.0 (99.24-100.0)	0.00 (-0.90, 0.93)	0.00 (-0.90, 0.91)	0.00 (-0.93, 0.91)
23F	97.24 (95.33-98.52)	98.56 (97.06-99.42)	99.79 (98.85-99.99)	-1.32 (-3.40, 0.76)	1.23 (-0.07, 2.52)	2.55 (0.80, 4.31)
Additional (vs. corresponding serotypes)						
1	99.58 (98.47-99.95)	57.49 (52.97-61.93)	100.0 (99.24-100.0)	42.08 (37.65, 46.51)	42.51 (38.11, 46.90)	0.42 (-0.25, 1.10)
3	98.09 (96.40-99.12)	45.17 (40.69-49.72)	96.06 (93.91-97.61)	52.91 (48.32, 57.50)	50.88 (46.13, 55.63)	-2.03 (-4.47, 0.41)
5	98.51 (96.96-99.40)	16.63 (13.43-20.24)	90.87 (87.94-93.29)	81.88 (78.40, 85.36)	74.24 (70.05, 78.43)	-7.64 (-10.84, -4.45)
6A	96.82 (94.80-98.21)	78.44 (74.52-82.01)	99.17 (97.89-99.77)	18.38 (14.39, 22.36)	20.73 (16.99, 24.47)	2.35 (0.32, 4.39)
7F	99.58 (98.47-99.95)	24.23 (20.49-28.29)	99.59 (98.51-99.95)	75.35 (71.49, 79.20)	75.36 (71.51, 79.20)	0.01 (-0.93, 0.95)
19A	100.0 (99.22-100.0)	97.13 (95.22-98.42)	100.0 (99.24-100.0)	2.87 (1.39, 4.36)	2.87 (1.39, 4.36)	0.00 (-0.93, 0.91)
Additional (vs. serotype with the lowest response among all 7 common serotypes)						
1	99.58 (98.47-99.95)	97.74 (95.99-98.87)	\	1.83 (0.18, 3.49)	2.26 (0.94, 3.58)	\
3	98.09 (96.40-99.12)	97.74 (95.99-98.87)	\	0.35 (-1.72, 2.42)	-1.68 (-3.86, 0.50)	\
5	98.51 (96.96-99.40)	97.74 (95.99-98.87)	\	0.77 (-1.19, 2.73)	-6.87 (-9.76, -3.98)	\
6A	96.82 (94.80-98.21)	97.74 (95.99-98.87)	\	-0.93 (-3.29, 1.43)	1.43 (-0.12, 2.98)	\
7F	99.58 (98.47-99.95)	97.74 (95.99-98.87)	\	1.83 (0.18, 3.49)	1.84 (0.40, 3.28)	\
19A	100.0 (99.22-100.0)	97.74 (95.99-98.87)	\	2.26 (0.75, 3.77)	2.26 (0.94, 3.58)	\

Post Complete Series

Serotypes	3 Months PCV13-TT N=475 % (95%CI)	3 Months Prevenar® N=487 % (95%CI)	2 Months PCV13-TT N=476 % (95%CI)	% (CI*) PCV13-TT [3M#] – Prevenar® [3M#]	% (CI*) PCV13-TT [2M#] – Prevenar® [3M#]	% (CI*) PCV13-TT [2M#] – PCV13-TT [3M#]
Common						
4	99.79 (98.83-99.99)	99.79 (98.86-99.99)	99.37 (98.17-99.87)	-0.01 (-0.66, 0.65)	-0.42 (-1.36, 0.51)	-0.42 (-1.36, 0.52)
6B	100.0 (99.23-100.0)	99.79 (98.86-99.99)	100.0 (99.23-100.0)	0.21 (-0.25, 0.67)	0.21 (-0.25, 0.67)	0.00 (-0.92, 0.92)
9V	100.0 (99.23-100.0)	100.0 (99.25-100.0)	100.0 (99.23-100.0)	0.00 (-0.90, 0.92)	0.00 (-0.90, 0.92)	0.00 (-0.92, 0.92)
14	99.79 (98.83-99.99)	100.0 (99.25-100.0)	100.0 (99.23-100.0)	-0.21 (-0.68, 0.26)	0.00 (-0.90, 0.92)	0.21 (-0.26, 0.68)
18C	99.79 (98.83-99.99)	99.59 (98.52-99.95)	99.58 (98.49-99.95)	0.20 (-0.60, 1.00)	-0.01 (-0.94, 0.92)	-0.21 (-1.02, 0.61)
19F	100.0 (99.23-100.0)	100.0 (99.25-100.0)	100.0 (99.23-100.0)	0.00 (-0.90, 0.92)	0.00 (-0.90, 0.92)	0.00 (-0.92, 0.92)
23F	100.0 (99.23-100.0)	99.79 (98.86-99.99)	99.79 (98.84-99.99)	0.21 (-0.25, 0.67)	-0.00 (-0.66, 0.65)	-0.21 (-0.68, 0.26)
Additional (vs. corresponding serotypes)						
1	99.79 (98.83-99.99)	91.38 (88.52-93.71)	99.79 (98.84-99.99)	8.41 (5.89, 10.94)	8.41 (5.89, 10.94)	0.00 (-0.67, 0.67)
3	99.16 (97.86-99.77)	92.20 (89.45-94.42)	98.95 (97.57-99.66)	6.96 (4.44, 9.48)	6.75 (4.20, 9.30)	-0.21 (-1.62, 1.20)
5	97.89 (96.16-98.99)	40.04 (35.66-44.55)	97.27 (95.38-98.54)	57.85 (53.31, 62.39)	57.23 (52.64, 61.82)	-0.63 (-2.86, 1.61)
6A	99.58 (98.49-99.95)	97.74 (95.99-98.87)	99.58 (98.49-99.95)	1.84 (0.40, 3.28)	1.84 (0.40, 3.28)	0.00 (-0.94, 0.94)
7F	100.0 (99.23-100.0)	66.74 (62.36-70.91)	100.0 (99.23-100.0)	33.26 (29.08, 37.45)	33.26 (29.08, 37.45)	0.00 (-0.92, 0.92)
19A	100.0 (99.23-100.0)	99.79 (98.86-99.99)	100.0 (99.23-100.0)	0.21 (-0.20, 0.61)	0.21 (-0.20, 0.61)	0.00 (-0.92, 0.92)
Additional (vs. serotype with the lowest response among all 7 common serotypes)						
1	99.79 (98.83-99.99)	99.59 (98.52-99.95)	\	0.20 (-0.60, 1.00)	0.20 (-0.50, 0.90)	\
3	99.16 (97.86-99.77)	99.59 (98.52-99.95)	\	-0.43 (-1.57, 0.71)	-0.64 (-1.72, 0.44)	\
5	97.89 (96.16-98.99)	99.59 (98.52-99.95)	\	-1.69 (-3.31, -0.08)	-2.32 (-3.89, -0.75)	\
6A	99.58 (98.49-99.95)	99.59 (98.52-99.95)	\	-0.01 (-0.94, 0.92)	-0.01 (-0.82, 0.80)	\
7F	100.0 (99.23-100.0)	99.59 (98.52-99.95)	\	0.41 (-0.24, 1.06)	0.41 (-0.16, 0.98)	\
19A	100.0 (99.23-100.0)	99.59 (98.52-99.95)	\	0.41 (-0.24, 1.06)	0.41 (-0.16, 0.98)	\

Note:
N: subjects included in PPS; %: IgG antibody positive rate; CI*: 2-sided 97.5% CI for common serotypes, 2-sided 97.5% CI for additional serotypes (vs. serotype with the lowest response among all 7 common serotypes), 2-sided 95% CI for additional serotypes (vs. corresponding serotypes).
*: For the additional serotypes, the reference value is serotype 18C from the Prevenar® (3 months of age) group.
\#: PCV13-TT [2M] representsPCV13-TT group included subjects aged 2 months ; PCV13-TT [3M] representsPCV13-TT group included subjects aged 3 months; Prevenar® [3M#] representsPrevenar group included subjects aged 3 months

Leaflet Kemasan: Informasi bagi Pengguna

VALENINA®

13-valent Pneumococcal Polysacharide Conjugate Vaccine

Bacalah seluruh isi leaflet ini dengan cermat sebelum anak Anda menerima vaksin ini karena leaflet ini memuat informasi penting untuk Anda.

- Simpan leaflet ini. Anda mungkin perlu membacanya kembali.
- Jika Anda memilki pertanyaan lebih lanjut, hubungi dokter, apoteker, atau perawat Anda.
- Vaksin ini diresepkan hanya untuk anak Anda. Jangan diberikan kepada orang lain. Itu dapat membahayakan mereka, sekali pun tanda-tanda penyakitnya sama dengan anak Anda.
- Jika anak Anda merasakan efek samping apa pun, hubungi dokter, apoteker, atau perawat Anda. Ini termasuk segala bentuk efek samping yang tidak tercantum di dalam leaflet ini. Lihat bagian 4.

Isi leaflet ini:

1. Penjelasan tentang Valenina® dan kegunaannya
2. Yang perlu Anda ketahui sebelum anak Anda menerima Valenina®
3. Cara pemberian Valenina®
4. Kemungkinan efek samping
5. Cara menyimpan Valenina®
6. Isi kemasan dan informasi lainnya

1. Penjelasan tentang Valenina® dan kegunaannya

Valenina® adalah suatu vaksin pneumokokus yang diberikan kepada:

- **Bayi dan anak-anak berusia 6 minggu hingga 5 tahun (sebelum ulang tahun ke-6)** untuk membantu mencegah terhadap penyakit invasif yang disebabkan oleh infeksi *Streptococcus pneumonia* yang disebabkan oleh 13 tipe bakteri *Streptococcus pneumonia*.

Produk ini tidak dapat menjamin semua penerima dapat terlindungi dari penyakit yang disebabkan oleh *Streptococcus pneumoniae*.

2. Yang perlu Anda ketahui sebelum anak Anda menerima Valenina®, Valenina® tidak boleh diberikan

- Jika anak Anda alergi (hipersensitif) terhadap bahan aktif atau terhadap bahan lainnya dalam vaksin ini (tercantum di bagian 6) atau terhadap vaksin lainnya yang mengandung difteria toksoid.
- Jika anak Anda menderita infeksi berat dengan suhu tinggi (di atas 38°C), penyakit akut dan serangan akut penyakit kronis. Jika anak Anda mengalami hal ini, maka vaksinasi akan ditunda hingga anak Anda merasa lebih baik. Infeksi minor, seperti pilek, tidak menjadi penghalang. Akan tetapi, konsultasikan terlebih dahulu dengan dokter, apoteker, atau perawat Anda.

Peringatan dan langkah-langkah pencegahan

Konsultasikan dengan dokter, apoteker, atau perawat Anda sebelum vaksinasi dilakukan jika anak Anda:

- Sedang atau pernah memiliki masalah kesehatan setelah pemberian Valenina® seperti reaksi alergi atau masalah pernapasan.
- Memiliki masalah perdarahan atau mudah memar. Perhatian harus diberikan pada vaksinasi pada penerima dengan trombositopenia, koagulopati atau mereka yang menerima pengobatan antikoagulan.
- Bayi prematur harus dipantau untuk potensi risiko apnea (henti napas atau gangguan irama pernapasan) selama rangkaian primer.
- Merupakan individu dengan sistem kekebalan yang lemah (misalnya keganasan atau sindrom nefrotik). Vaksinasi pada kelompok khusus ini harus dipertimbangkan secara individual.

Obat/vaksin lain dan Valenina®

Penggunaan PCV13-TT tidak menggantikan penggunaan *23-valent Pneumococcal Polysaccharide Vaccine* pada anak-anak ≥ usia 24 bulan dengan kondisi seperti *sickle cell disease* (kelainan bentuk sel darah merah), asplenia (kondisi limpa abnormal), infeksi HIV, penyakit kronis, atau mereka yang imunokompromais (penurunan sistem imun).

Dalam keadaan apa pun, tetanus toksoid yang terkandung dalam vaksin tidak boleh menggantikan imunisasi rutin vaksin tetanus atau vaksin yang mengandung tetanus.

Informasikan kepada dokter, apoteker atau perawat Anda jika anak Anda sedang, baru-baru ini atau mungkin akan meminum obat-obatan lain, atau baru-baru ini telah menerima vaksin lain.

Kehamilan dan menyusui

Jika Anda hamil atau menyusui, berpikir Anda mungkin sedang hamil atau berencana untuk hamil, konsultasikan dengan dokter atau apoteker Anda sebelum menerima vaksin ini.

3. Cara Pemberian Valenina®

Dokter atau perawat akan menyuntikan dosis vaksin yang dianjurkan (0,5 ml) ke bagian tengah paha pada bayi Anda dan lengan atas pada balita dan anak-anak.

Bayi berusia 2 atau 3 bulan

Biasanya, anak Anda semestinya akan menerima rangkaian berupa empat kali suntikan vaksin.

Untuk vaksinasi pada bayi atau anak Anda yang berusia 2 bulan:

- Suntikan pertama dapat diberikan paling cepat sejak usia enam minggu.
- Setiap suntikan akan diberikan dengan jarak setidaknya dua bulan.
- Suntikan keempat akan diberikan di antara usia 12 dan 15 bulan.
- Anda akan diberi tahu kapan anak Anda harus kembali untuk suntikan berikutnya.

Untuk vaksinasi pada bayi atau anak Anda yang berusia 3 bulan:

- Suntikan pertama dapat diberikan pada usia 3 bulan.
- Setiap suntikan akan diberikan dengan jarak setidaknya satu bulan.
- Suntikan keempat akan diberikan di antara usia 12 dan 15 bulan.

Menurut rekomendasi resmi, jadwal alternatif dapat digunakan oleh penyedia layanan kesehatan Anda. Silakan berkonsultasi dengan dokter, apoteker, atau perawat untuk informasi lebih lanjut.

Bayi dan anak-anak di atas usia 7 bulan hingga 5 tahun yang belum divaksinasi

Bayi yang berusia **7 sampai 11 bulan** harus menerima tiga kali suntikan. Dua suntikan pertama akan diberikan dengan jarak setidaknya 2 bulan. Suntikan ketiga akan diberikan di saat anak berusia satu tahun, dengan jarak setidaknya 2 bulan dari suntikan kedua.

Anak-anak yang berusia **12 sampai 23 bulan** harus menerima dua kali suntikan. Setiap suntikan akan diberikan dengan jarak setidaknya 2 bulan.

Anak-anak yang berusia **2 sampai 5 tahun** (sebelum ulang tahun ke-6) harus menerima satu kali suntikan.

Penting kiranya mengikuti petunjuk dari dokter, apoteker, atau perawat Anda sehingga anak Anda mendapatkan rangkaian suntikan yang lengkap.

Jika Anda lupa untuk kembali pada waktu yang dijadwalkan, mintalah saran dari dokter, apoteker, atau perawat Anda.

4.Kemungkinan Efek Samping

Seperti semua vaksin yang ada, Valenina® dapat menyebabkan efek samping, meskipun tidak semua orang mengalaminya.

Berikut ini efek samping yang dilaporkan terkait pemberian Valenina® pada bayi dan anak- anak (usia 6 minggu hingga 5 tahun/sebelum ulang tahun ke-6):

Efek samping yang sangat umum (frekuensi ≥ 10%) adalah:

- Demam
- Diare
- Kemerahan

Efek samping yang umum (frekuensi ≥ 1% sampai < 10%) adalah:

- Menangis
- Batuk
- Mual/muntah
- Kelelahan/penurunan tingkat kesadaran
- Reaksi alergi
- Pembengkakan
- Nyeri
- Penonjolan kulit yang kemerahan

Efek samping yang tidak umum (frekuensi ≥ 0,1% sampai < 1%) adalah:

- Nyeri otot
- Gatal pada kulit

Efek samping yang jarang (frekuensi ≥ 0,01% sampai < 0,1%) adalah:

- Ruam

Final Artwork	
Item Name	Brochure PCV-13 Front
Dimension	570 x200 mm
Item Code	N/A
CC no.	CC-EBI-OT-007-23
Font	See information on the side
Color	See information on the side
Material	HVS 60 gsm
Revision	00

Font :

VALENINA® ________ Work Sans Extrabold 8pt

13-valent Pneumococcal Polysaccharide Conjugate Vaccine ________ Calibri bold 6.4pt

Others ________ Source Sans Pro 4.5pt

COLOR:

P Black C0; M0; Y0; K100

P2925C

PT. Etana Biotechnologies Indonesia

Pack. Dev. Spv.	R&D Manager	Business Development Head	Regulatory Affairs Director	Medical	QA Manager
Indri Indriyani	Christian Karol S	M. Indra Lamora	Yustina Ari	dr. Alfira Belasari	Happy Monda P.

DISETUJUI OLEH BPOM: 21/06/24

ID EREG100007VR12400033

Melaporkan efek samping
Jika anak Anda merasakan efek samping apa pun, hubungi dokter, apoteker, atau perawat Anda. Ini termasuk segala bentuk efek samping yang tidak tercantum di dalam leaflet ini. Dengan melaporkan efek samping, Anda dapat membantu memberikan informasi lebih.

5. Cara menyimpan Valenina®
Jauhkan vaksin ini dari pandangan dan jangkauan anak-anak.
Jangan menggunakan vaksin ini setelah tanggal kedaluwarsa yang tertera pada karton dan label setelah tanda EXP.
Simpan dan transportasikan di dalam lemari pendingin (2°C - 8°C). Lindungi dari cahaya.
Jangan dibekukan. Buang jika vaksin sudah membeku.
Selama penyimpanan, akan teramati adanya endapan putih dan supernatan yang bening. Kondisi ini tidaklah menunjukkan tanda kerusakan.
Jangan membuang obat melalui saluran pembuangan air atau bersama sampah rumah tangga. Tanyakan apoteker Anda cara membuang vaksin yang sudah tidak digunakan lagi. Langkah-langkah ini akan membantu melindungi lingkungan.

6. Isi kemasan dan Informasi lainnya
Kandungan Valenina®
Zat aktifnya adalah:
- 2,5 µg polisakarida untuk serotipe 3, 5, 6A, 9V
- 2,6 µg polisakarida untuk serotipe 1,19A
- 2,75 µg polisakarida untuk serotipe 14, 19F
- 2,85 µg polisakarida untuk serotipe 7F
- 3,0 µg polisakarida untuk serotipe 4, 23F
- 3,25 µg polisakarida untuk serotipe 18C
- 6,0 µg polisakarida untuk serotipe 6B

Dikonjugasikan ke protein pembawa tetanus toxoid dan dijerapkan pada aluminium fosfat (0,5 mg aluminium).

Bahan lainnya adalah natrium klorida, sodium dihydrogen fosfat monohidrat, disodium hydrogen fosfat dodecahydrate, air untuk injeksi.

Seperti apa wujud Valenina® dan isi kemasannya
Vaksin berupa suspensi putih untuk injeksi yang disediakan dalam *pre-filled syringe* (0,5 mL) dan vial (0,5 mL).

Dus, 1 *pre-filled syringe* @ 0,5 ml (No. Reg. DKLXXXXXXXXXXXX)

HARUS DENGAN RESEP DOKTER

Diproduksi oleh:
PT. Etana Biotechnologies Indonesia
Jakarta, Indonesia

etana
Biotech

Informasi berikut ini ditujukan hanya untuk tenaga kesehatan profesional

Selama penyimpanan, endapan putih dan supernatan jernih dapat teramati

Periksa secara visual keberadaan partikel benda asing dan/atau wujud fisik yang tidak normal; jangan digunakan jika ditemukan salah satunya.
Sebelum mengeluarkan udara dari alat suntik, kocok dengan baik untuk membentuk suspensi putih yang homogen.

Berikan seluruh dosis.

Valenina® hanya untuk penggunaan intramuskular. Jangan diberikan secara intravena atau dengan injeksi intramuskular gluteal, dan pastikan jarum suntik tidak menusuk pembuluh darah selama injeksi.
Dilarang mencampur Valenina® dengan vaksin lain dalam alat suntik yang sama.
Valenina® (khusus kemasan vial) harus segera disuntikkan setelah diambil ke dalam alat suntik.

Valenina® dapat diberikan pada waktu yang sama dengan vaksin anak lainnya; dalam hal ini harus digunakan pada lokasi vaksinasi yang berbeda.

Setiap produk yang tidak digunakan atau materi limbah harus dibuang sesuai dengan persyaratan setempat.

Table 8 IgG Antibody GMCs in Subjects Aged 2 Months and 3 Months following Immunizations (PPS)

Serotypes	Post Primary Series						Post Complete Series					
	3 Months		2 Months	Ratio (CI*)			3 Months		2 Months	Ratio (CI*)		
	PCV13-TT N=471 GMC (95%CI)	Prevenar® N=487 GMC (95%CI)	PCV13-TT N=482 GMC (95%CI)	PCV13-TT [3M#]/ Prevenar® [3M#]	PCV13-TT [2M#]/ Prevenar® [3M#]	PCV13-TT [2M#]/ PCV13-TT [3M#]	PCV13-TT N=475 GMC (95%CI)	Prevenar® N=487 GMC (95%CI)	PCV13-TT N=476 GMC (95%CI)	PCV13-TT [3M#]/ Prevenar® [3M#]	PCV13-TT [2M#]/ Prevenar® [3M#]	PCV13-TT [2M#]/ PCV13-TT [3M#]
Common												
4	4.51 (4.20-4.84)	7.79 (7.22-8.41)	2.43 (2.28-2.60)	0.58 (0.51, 0.65)	0.31 (0.28, 0.35)	0.54 (0.48, 0.60)	3.19 (2.96-3.44)	4.27 (3.98-4.59)	2.07 (1.92-2.22)	0.75 (0.66, 0.84)	0.48 (0.43, 0.54)	0.65 (0.58, 0.73)
6B	1.25 (1.11-1.42)	3.52 (3.25-3.81)	3.72 (3.37-4.10)	0.36 (0.30, 0.42)	1.06 (0.91, 1.22)	2.97 (2.47, 3.56)	10.01 (9.30-10.79)	11.70 (10.78-12.70)	8.60 (7.93-9.32)	0.86 (0.75, 0.97)	0.73 (0.64, 0.84)	0.86 (0.76, 0.97)
9V	3.72 (3.45-4.02)	4.47 (4.19-4.78)	3.66 (3.40-3.94)	0.83 (0.74, 0.93)	0.82 (0.73, 0.92)	0.98 (0.87, 1.11)	4.22 (3.90-4.56)	3.87 (3.62-4.14)	3.83 (3.56-4.12)	1.09 (0.97, 1.23)	0.99 (0.88, 1.11)	0.91 (0.80, 1.03)
14	10.38 (9.57-11.27)	16.53 (15.09-18.11)	10.25 (9.46-11.11)	0.63 (0.55, 0.72)	0.62 (0.54, 0.71)	0.99 (0.87, 1.13)	13.97 (12.94-15.09)	17.89 (16.77-19.09)	11.61 (10.85-12.44)	0.78 (0.70, 0.88)	0.65 (0.58, 0.72)	0.83 (0.74, 0.93)
18C	2.91 (2.68-3.15)	4.80 (4.37-5.28)	2.04 (1.87-2.23)	0.61 (0.52, 0.70)	0.43 (0.37, 0.49)	0.70 (0.61, 0.81)	2.44 (2.27-2.63)	3.90 (3.59-4.23)	2.04 (1.90-2.18)	0.63 (0.55, 0.71)	0.52 (0.46, 0.59)	0.83 (0.74, 0.94)
19F	6.95 (6.49-7.45)	9.00 (8.43-9.60)	5.46 (5.14-5.80)	0.77 (0.69, 0.86)	0.61 (0.55, 0.67)	0.79 (0.71, 0.87)	12.18 (11.25-13.20)	7.84 (7.33-8.38)	8.76 (8.16-9.39)	1.56 (1.38, 1.75)	1.12 (1.00, 1.25)	0.72 (0.64, 0.81)
23F	2.93 (2.65-3.23)	4.44 (4.08-4.82)	3.86 (3.53-4.21)	0.66 (0.57, 0.76)	0.87 (0.76, 1.00)	1.32 (1.13, 1.53)	6.9 (6.39-7.45)	10.81 (9.91-11.80)	5.70 (5.25-6.18)	0.64 (0.56, 0.73)	0.53 (0.46, 0.60)	0.83 (0.73, 0.94)
Additional (vs. corresponding serotypes)												
1	2.15 (2.01-2.30)	0.30 (0.26-0.34)	2.09 (1.95-2.23)	7.17 (6.14, 8.37)	6.96 (5.97, 8.12)	0.97 (0.87, 1.09)	2.79 (2.61-2.99)	0.67 (0.62-0.72)	1.98 (1.86-2.12)	4.18 (3.76, 4.65)	2.97 (2.68, 3.30)	0.71 (0.64, 0.79)
3	1.67 (1.56-1.79)	0.33 (0.31-0.36)	1.41 (1.32-1.50)	5.02 (4.55, 5.53)	4.22 (3.83, 4.65)	0.84 (0.76, 0.94)	1.89 (1.77-2.01)	1.02 (0.95-1.09)	1.53 (1.44-1.64)	1.86 (1.69, 2.04)	1.51 (1.37, 1.66)	0.81 (0.73, 0.90)
5	1.88 (1.75-2.02)	0.05 (0.04-0.06)	0.79 (0.73-0.85)	40.29 (32.02, 50.69)	16.88 (13.42, 21.24)	0.42 (0.37, 0.47)	1.58 (1.47-1.70)	0.16 (0.14-0.19)	1.13 (1.06-1.21)	9.63 (8.06, 11.51)	6.92 (5.80, 8.25)	0.72 (0.64, 0.80)
6A	1.96 (1.77-2.16)	0.58 (0.50-0.67)	3.28 (3.01-3.57)	3.38 (2.83, 4.03)	5.65 (4.78, 6.69)	1.67 (1.44, 1.95)	5.82 (5.32-6.37)	3.80 (3.44-4.21)	4.79 (4.39-5.22)	1.53 (1.34, 1.75)	1.26 (1.10, 1.44)	0.82 (0.71, 0.95)
7F	5.47 (5.06-5.92)	0.05 (0.04-0.07)	4.76 (4.42-5.13)	105.38 (82.43, 134.72)	91.73 (72.03, 116.82)	0.87 (0.77, 0.98)	4.59 (4.29-4.91)	0.31 (0.26-0.36)	4.05 (3.79-4.32)	15.01 (12.58, 17.91)	13.22 (11.09, 15.76)	0.88 (0.79, 0.98)
19A	3.85 (3.62-4.09)	1.06 (0.97-1.16)	3.12 (2.95-3.30)	3.63 (3.25, 4.06)	2.94 (2.64, 3.28)	0.81 (0.74, 0.89)	13.34 (12.37-14.39)	3.00 (2.78-3.24)	9.32 (8.66-10.03)	4.45 (4.00, 4.95)	3.11 (2.80, 3.45)	0.70 (0.62, 0.79)
Additional (vs. serotype with the lowest response among all 7 common serotypes)*												
1	2.15 (2.01-2.30)	3.52 (3.25-3.81)	\	0.61 (0.54, 0.69)	0.59 (0.53, 0.66)	\	2.79 (2.61-2.99)	3.87 (3.62-4.14)	\	0.72 (0.65, 0.80)	0.51 (0.47, 0.56)	\
3	1.67 (1.56-1.79)	3.52 (3.25-3.81)	\	0.48 (0.42, 0.54)	0.40 (0.36, 0.44)	\	1.89 (1.77-2.01)	3.87 (3.62-4.14)	\	0.49 (0.44, 0.54)	0.40 (0.36, 0.44)	\
5	1.88 (1.75-2.02)	3.52 (3.25-3.81)	\	0.54 (0.47, 0.61)	0.22 (0.20, 0.25)	\	1.58 (1.47-1.70)	3.87 (3.62-4.14)	\	0.41 (0.37, 0.46)	0.29 (0.27, 0.32)	\
6A	1.96 (1.77-2.16)	3.52 (3.25-3.81)	\	0.56 (0.48, 0.64)	0.93 (0.83, 1.05)	\	5.82 (5.32-6.37)	3.87 (3.62-4.14)	\	1.50 (1.32, 1.71)	1.24 (1.11, 1.38)	\
7F	5.47 (5.06-5.92)	3.52 (3.25-3.81)	\	1.56 (1.37, 1.77)	1.35 (1.22, 1.51)	\	4.59 (4.29-4.91)	3.87 (3.62-4.14)	\	1.19 (1.06, 1.32)	1.05 (0.95, 1.15)	\
19A	3.85 (3.62-4.09)	3.52 (3.25-3.81)	\	1.09 (0.97, 1.23)	0.89 (0.80, 0.98)	\	13.34 (12.37-14.39)	3.87 (3.62-4.14)	\	3.45 (3.07, 3.87)	2.41 (2.18, 2.66)	\

Note: N: subjects included in PPS; Ratio: GMC/GMC; CI*: 2-sided 97.5% CI for common serotypes, 2-sided 97.5% CI for additional serotypes (vs. serotype with the lowest response among all 7 common serotypes), 2-sided 95% CI for additional serotypes (vs. corresponding serotypes).
*: For the additional serotypes, the reference value is serotype 6B from the Prevenar® (3 months of age) group.
#: PCV13-TT [2M] represents PCV13-TT group included subjects aged 2 months; PCV13-TT [3M] represents PCV13-TT group included subjects aged 3 months; Prevenar® [3M#] represents Prevenar group included subjects aged 3 months.

Table 9 Proportion of Subjects with IgG Antibody Concentration ≥ 0.35 µg/mL in Subjects Aged 7 through 71 Months (PPS)

Serotypes		Post Primary Immunizations						Post Booster Immunization	
		7-11 Months		12-23 Months		24-71 Months		7-11 Months	
		PCV13-TT N=185 %(CI*)	Prevenar® N=189 %(CI*)	PCV13-TT N=189 %(CI*)	Prevenar® N=189 %(CI*)	PCV13-TT N=198 %(CI*)	Prevenar® N=199 %(CI*)	PCV13-TT N=186 %(CI*)	Prevenar® N=189 %(CI*)
Common	4	100.0 (98.03-100.0)	100.0 (98.07-100.0)	100.0 (98.07-100.0)	99.47 (97.09-99.99)	100.0 (98.15-100.0)	100.0 (98.16-100.0)	100.0 (98.04-100.0)	100.0 (98.07-100.0)
	6B	96.76 (93.07-98.80)	99.47 (97.09-99.99)	100.0 (98.07-100.0)	98.41 (95.43-99.67)	100.0 (98.15-100.0)	98.99 (96.42-99.88)	100.0 (98.04-100.0)	100.0 (98.07-100.0)
	9V	97.30 (93.81-99.12)	97.88 (94.67-99.42)	100.0 (98.07-100.0)	98.94 (96.23-99.87)	98.48 (95.64-99.69)	98.99 (96.42-99.88)	99.46 (97.04-99.99)	100.0 (98.07-100.0)
	14	100.0 (98.03-100.0)	100.0 (98.07-100.0)	100.0 (98.07-100.0)	100.0 (98.07-100.0)	99.49 (97.22-99.99)	99.50 (97.23-99.99)	100.0 (98.04-100.0)	100.0 (98.07-100.0)
	18C	99.46 (97.03-99.99)	99.47 (97.09-99.99)	100.0 (98.07-100.0)	100.0 (98.07-100.0)	98.99 (96.40-99.88)	100.0 (98.16-100.0)	99.46 (97.04-99.99)	99.47 (97.09-99.99)
	19F	100.0 (98.03-100.0)	100.0 (98.07-100.0)	100.0 (98.07-100.0)	100.0 (98.07-100.0)	100.0 (98.15-100.0)	100.0 (98.16-100.0)	100.0 (98.04-100.0)	100.0 (98.07-100.0)
	23F	97.30 (93.81-99.12)	96.83 (93.22-98.83)	99.47 (97.09-99.99)	99.47 (97.09-99.99)	98.99 (96.40-99.88)	97.99 (94.93-99.45)	100.0 (98.04-100.0)	100.0 (98.07-100.0)
Additional (vs. corresponding serotypes)	1	98.92 (96.15-99.87)	75.66 (68.90-81.60)	100.0 (98.07-100.0)	70.37 (63.31-76.78)	98.48 (95.64-99.69)	66.33 (59.31-72.86)	100.0 (98.04-100.0)	82.54 (76.36-87.67)
	3	97.84 (94.56-99.41)	61.90 (54.57-68.86)	98.41 (95.43-99.67)	47.62 (40.32-54.99)	88.89 (83.66-92.90)	44.72 (37.69-51.92)	98.92 (96.17-99.87)	68.78 (61.65-75.31)
	5	91.35 (86.34-94.98)	44.44 (37.23-51.83)	96.83 (93.22-98.83)	53.44 (46.06-60.71)	98.48 (95.64-99.69)	63.82 (56.72-70.50)	93.01 (88.34-96.23)	40.74 (33.67-48.11)
	6A	95.68 (91.66-98.11)	77.78 (71.17-83.49)	98.41 (95.43-99.67)	93.65 (89.17-96.68)	96.46 (92.85-98.57)	91.96 (87.27-95.33)	98.39 (95.36-99.67)	93.12 (88.53-96.29)
	7F	99.46 (97.03-99.99)	46.03 (38.77-53.42)	100.0 (98.07-100.0)	71.43 (64.42-77.75)	98.99 (96.40-99.88)	71.36 (64.54-77.53)	100.0 (98.04-100.0)	73.02 (66.09-79.20)
	19A	100.0 (98.03-100.0)	97.88 (94.67-99.42)	100.0 (98.07-100.0)	99.47 (97.09-99.99)	100.0 (98.15-100.0)	99.50 (97.23-99.99)	100.0 (98.04-100.0)	100.0 (98.07-100.0)

Note: N: subjects included in PPS; CI*: 2-sided 95% CI for IgG antibody positive rate.

Table 9 Proportion of Subjects with IgG Antibody Concentration ≥ 0.35 µg/mL in Subjects Aged 7 through 71 Months (PPS)

Serotypes		Post Primary Immunizations						Post Booster Immunization	
		7-11 Months		12-23 Months		24-71 Months		7-11 Months	
		PCV13-TT N=185 %(CI*)	Prevenar® N=189 %(CI*)	PCV13-TT N=189 %(CI*)	Prevenar® N=189 %(CI*)	PCV13-TT N=198 %(CI*)	Prevenar® N=199 %(CI*)	PCV13-TT N=186 %(CI*)	Prevenar® N=189 %(CI*)
Additional (vs. serotype with the lowest response among all 7 common serotypes)	1	98.92 (96.15-99.87)	96.83 (93.22-98.83)	100.0 (98.07-100.0)	98.41 (95.43-99.67)	98.48 (95.64-99.69)	97.99 (94.93-99.45)	100.0 (98.04-100.0)	99.47 (97.09-99.99)
	3	97.84 (94.56-99.41)	96.83 (93.22-98.83)	98.41 (95.43-99.67)	98.41 (95.43-99.67)	88.89 (83.66-92.90)	97.99 (94.93-99.45)	98.92 (96.17-99.87)	99.47 (97.09-99.99)
	5	91.35 (86.34-94.98)	96.83 (93.22-98.83)	96.83 (93.22-98.83)	98.41 (95.43-99.67)	98.48 (95.64-99.69)	97.99 (94.93-99.45)	93.01 (88.34-96.23)	99.47 (97.09-99.99)
	6A	95.68 (91.66-98.11)	96.83 (93.22-98.83)	98.41 (95.43-99.67)	98.41 (95.43-99.67)	96.46 (92.85-98.57)	97.99 (94.93-99.45)	98.39 (95.36-99.67)	99.47 (97.09-99.99)
	7F	99.46 (97.03-99.99)	96.83 (93.22-98.83)	100.0 (98.07-100.0)	98.41 (95.43-99.67)	98.99 (96.40-99.88)	97.99 (94.93-99.45)	100.0 (98.04-100.0)	99.47 (97.09-99.99)
	19A	100.0 (98.03-100.0)	96.83 (93.22-98.83)	100.0 (98.07-100.0)	98.41 (95.43-99.67)	100.0 (98.15-100.0)	97.99 (94.93-99.45)	100.0 (98.04-100.0)	99.47 (97.09-99.99)

Note: N: subjects included in PPS; CI*: 2-sided 95% CI for IgG antibody positive rate.

Table 10 IgG Antibody GMCs in Subjects Aged 7 through 71 Months (PPS)

Serotypes		Post Primary Immunizations						Post Booster Immunization	
		7-11 Months		12-23 Months		24-71 Months		7-11 Months	
		PCV13-TT N=185 GMC (CI*)	Prevenar® N=189 GMC (CI*)	PCV13-TT N=189 GMC (CI*)	Prevenar® N=189 GMC(CI*)	PCV13-TT N=198 GMC(CI*)	Prevenar® N=199 GMC (CI*)	PCV13-TT N=186 GMC (CI*)	Prevenar® N=189 GMC (CI*)
Common	4	4.26 (3.86-4.71)	4.23 (3.88-4.62)	5.01 (4.60-5.45)	5.08 (4.63-5.58)	8.90 (7.95-9.96)	8.58 (7.63-9.66)	3.06 (2.76-3.38)	3.12 (2.85-3.41)
	6B	2.90 (2.46-3.42)	2.20 (1.92-2.52)	5.42 (4.86-6.04)	2.71 (2.35-3.11)	7.75 (6.58-9.12)	3.63 (3.04-4.32)	5.62 (5.01-6.32)	4.57 (4.08-5.11)
	9V	2.38 (2.09-2.71)	2.76 (2.43-3.12)	2.97 (2.68-3.30)	2.95 (2.64-3.30)	3.84 (3.35-4.41)	3.94 (3.36-4.62)	2.91 (2.58-3.29)	3.67 (3.31-4.07)
	14	8.54 (7.60-9.60)	16.17 (14.53-17.99)	9.20 (8.28-10.22)	14.98 (13.51-16.61)	10.20 (8.40-12.38)	15.75 (12.82-19.34)	13.94 (12.54-15.51)	19.49 (17.94-21.17)
	18C	3.78 (3.30-4.34)	3.44 (3.08-3.84)	5.03 (4.63-5.46)	3.92 (3.56-4.31)	8.82 (7.56-10.29)	7.47 (6.45-8.66)	2.97 (2.62-3.36)	3.32 (3.00-3.67)
	19F	7.21 (6.43-8.08)	4.09 (3.70-4.52)	8.80 (8.10-9.55)	4.20 (3.79-4.65)	11.45 (10.05-13.04)	5.71 (4.98-6.54)	7.54 (6.84-8.31)	3.92 (3.56-4.31)
	23F	3.56 (3.10-4.10)	2.70 (2.36-3.09)	4.32 (3.89-4.79)	2.96 (2.61-3.36)	4.42 (3.80-5.14)	4.29 (3.56-5.17)	4.53 (4.01-5.12)	4.21 (3.77-4.71)
Additional (vs. corresponding serotypes)	1	2.23 (2.03-2.45)	0.47 (0.40-0.56)	2.25 (2.07-2.44)	0.42 (0.35-0.50)	2.06 (1.84-2.30)	0.31 (0.26-0.39)	1.98 (1.82-2.15)	0.58 (0.53-0.65)
	3	1.32 (1.20-1.45)	0.46 (0.41-0.51)	1.06 (0.98-1.14)	0.39 (0.34-0.45)	0.84 (0.75-0.94)	0.38 (0.33-0.45)	1.51 (1.38-1.66)	0.53 (0.48-0.59)
	5	0.82 (0.73-0.91)	0.19 (0.15-0.25)	1.01 (0.91-1.12)	0.27 (0.22-0.32)	1.60 (1.43-1.79)	0.31 (0.25-0.38)	0.86 (0.78-0.95)	0.24 (0.20-0.29)
	6A	1.79 (1.51-2.12)	0.54 (0.41-0.72)	2.46 (2.08-2.92)	1.17 (1.01-1.35)	2.35 (2.00-2.76)	1.29 (1.05-1.60)	2.99 (2.64-3.37)	1.63 (1.43-1.87)
	7F	5.73 (5.04-6.51)	0.14 (0.10-0.20)	5.47 (5.04-5.94)	0.41 (0.33-0.52)	4.60 (4.00-5.28)	0.43 (0.33-0.56)	4.91 (4.46-5.39)	0.46 (0.39-0.55)
	19A	5.06 (4.54-5.64)	1.50 (1.29-1.74)	7.81 (7.08-8.61)	2.67 (2.28-3.12)	9.56 (8.47-10.79)	3.32 (2.85-3.88)	6.28 (5.71-6.91)	2.17 (1.96-2.40)
Additional (vs. serotype with the lowest response among all 7 common serotypes)	1	2.23 (2.03-2.45)	2.20 (1.92-2.52)	2.25 (2.07-2.44)	2.71 (2.35-3.11)	2.06 (1.84-2.30)	3.63 (3.04-4.32)	1.98 (1.82-2.15)	3.12 (2.85-3.41)
	3	1.32 (1.20-1.45)	2.20 (1.92-2.52)	1.06 (0.98-1.14)	2.71 (2.35-3.11)	0.84 (0.75-0.94)	3.63 (3.04-4.32)	1.51 (1.38-1.66)	3.12 (2.85-3.41)
	5	0.82 (0.73-0.91)	2.20 (1.92-2.52)	1.01 (0.91-1.12)	2.71 (2.35-3.11)	1.60 (1.43-1.79)	3.63 (3.04-4.32)	0.86 (0.78-0.95)	3.12 (2.85-3.41)
	6A	1.79 (1.51-2.12)	2.20 (1.92-2.52)	2.46 (2.08-2.92)	2.71 (2.35-3.11)	2.35 (2.00-2.76)	3.63 (3.04-4.32)	2.99 (2.64-3.37)	3.12 (2.85-3.41)
	7F	5.73 (5.04-6.51)	2.20 (1.92-2.52)	5.47 (5.04-5.94)	2.71 (2.35-3.11)	4.60 (4.00-5.28)	3.63 (3.04-4.32)	4.91 (4.46-5.39)	3.12 (2.85-3.41)
	19A	5.06 (4.54-5.64)	2.20 (1.92-2.52)	7.81 (7.08-8.61)	2.71 (2.35-3.11)	9.56 (8.47-10.79)	3.63 (3.04-4.32)	6.28 (5.71-6.91)	3.12 (2.85-3.41)

Note: N: subjects included in PPS; CI*: 2-sided 95% CI for IgG GMC.

Table 11 Seroconversion Rates of OPA Antibody (Titer ≥ 1:8) in Each Age Group following Immunizations (PPS)

Serotypes	Post Primary Series									Post Complete Series				
	3 Months		2 Months	7-11 Months		12-23 Months		24-71 Months		3 Months		2 Months	7-11 Months	
	PCV13-TT N=93 %(CI*)	Prevenar® N=96 %(CI*)	PCV13-TT N=97 %(CI*)	PCV13-TT N=96 %(CI*)	Prevenar® N=95 %(CI*)	PCV13-TT N=92 %(CI*)	Prevenar® N=93 %(CI*)	PCV13-TT N=99 %(CI*)	Prevenar® N=100 %(CI*)	PCV13-TT N=96 %(CI*)	Prevenar® N=97 %(CI*)	PCV13-TT N=92 %(CI*)	PCV13-TT N=93 %(CI*)	Prevenar® N=95 %(CI*)
Common														
4	100.0 (96.11-100.0)	100.0 (96.23-100.0)	98.97 (94.39-99.97)	100.0 (96.23-100.0)	100.0 (96.19-100.0)	100.0 (96.07-100.0)	100.0 (96.11-100.0)	100.0 (96.34-100.0)	96.00 (90.07-98.90)	100.0 (96.23-100.0)	100.0 (96.27-100.0)	100.0 (96.07-100.0)	100.0 (96.11-100.0)	100.0 (96.19-100.0)
6B	89.25 (81.11-94.72)	98.96 (94.33-99.97)	92.78 (85.70-97.05)	81.25 (72.00-88.49)	89.47 (81.49-94.84)	94.57 (87.77-98.21)	91.40 (83.75-96.21)	97.98 (92.89-99.75)	98.00 (92.96-99.76)	98.96 (94.33-99.97)	97.94 (92.75-99.75)	100.0 (96.07-100.0)	93.55 (86.48-97.60)	95.79 (89.57-98.84)
9V	100.0 (96.11-100.0)	100.0 (96.23-100.0)	100.0 (96.27-100.0)	100.0 (96.23-100.0)	100.0 (96.19-100.0)	100.0 (96.07-100.0)	100.0 (96.11-100.0)	100.0 (96.34-100.0)	100.0 (96.38-100.0)	100.0 (96.23-100.0)	100.0 (96.27-100.0)	100.0 (96.07-100.0)	100.0 (96.11-100.0)	100.0 (96.19-100.0)
14	100.0 (96.11-100.0)	100.0 (96.23-100.0)	100.0 (96.27-100.0)	98.96 (94.33-99.97)	97.89 (92.60-99.74)	100.0 (96.07-100.0)	100.0 (96.11-100.0)	92.93 (85.97-97.11)	95.00 (88.72-98.36)	100.0 (96.23-100.0)	100.0 (96.27-100.0)	100.0 (96.07-100.0)	100.0 (96.11-100.0)	100.0 (96.19-100.0)
18C	100.0 (96.11-100.0)	98.96 (94.33-99.97)	100.0 (96.27-100.0)	98.96 (94.33-99.97)	98.95 (94.27-99.97)	100.0 (96.07-100.0)	100.0 (96.11-100.0)	100.0 (96.34-100.0)	99.00 (94.55-99.97)	100.0 (96.23-100.0)	98.97 (94.39-99.97)	100.0 (96.07-100.0)	100.0 (96.11-100.0)	98.95 (94.27-99.97)
19F	100.0 (96.11-100.0)	97.92 (92.68-99.75)	98.97 (94.39-99.97)	98.96 (94.33-99.97)	91.58 (84.08-96.29)	98.91 (94.09-99.97)	92.47 (85.10-96.92)	98.99 (94.50-99.97)	94.00 (87.40-97.77)	100.0 (96.23-100.0)	96.91 (91.23-99.36)	100.0 (96.07-100.0)	100.0 (96.11-100.0)	93.68 (86.76-97.65)
23F	95.70 (89.35-98.82)	98.96 (94.33-99.97)	95.88 (89.78-98.87)	91.67 (84.24-96.33)	94.74 (88.14-98.27)	98.91 (94.09-99.97)	96.77 (90.86-99.33)	96.97 (91.40-99.37)	99.00 (94.55-99.97)	98.96 (94.33-99.97)	98.97 (94.39-99.97)	100.0 (96.07-100.0)	97.85 (92.45-99.74)	95.79 (89.57-98.84)

Note: N: subjects included in PPS; CI*: 2-sided 95% CI for OPA antibody positive rate.

Table 11 Seroconversion Rates of OPA Antibody (Titer ≥ 1:8) in Each Age Group following Immunizations (PPS)

Serotypes	Post Primary Series									Post Complete Series				
	3 Months		2 Months	7-11 Months		12-23 Months		24-71 Months		3 Months		2 Months	7-11 Months	
	PCV13-TT N=93 %(CI*)	Prevenar® N=96 %(CI*)	PCV13-TT N=97 %(CI*)	PCV13-TT N=96 %(CI*)	Prevenar® N=95 %(CI*)	PCV13-TT N=92 %(CI*)	Prevenar® N=93 %(CI*)	PCV13-TT N=99 %(CI*)	Prevenar® N=100 %(CI*)	PCV13-TT N=96 %(CI*)	Prevenar® N=97 %(CI*)	PCV13-TT N=92 %(CI*)	PCV13-TT N=93 %(CI*)	Prevenar® N=95 %(CI*)
Additional (vs. corresponding serotypes)														
1	83.87 (74.80-90.68)	0.00 (0.00-3.77)	91.75 (84.39-96.37)	92.71 (85.55-97.02)	5.26 (1.73-11.86)	88.04 (79.61-93.88)	3.23 (0.67-9.14)	43.43 (33.50-53.77)	1.00 (0.03-5.45)	97.92 (92.68-99.75)	4.12 (1.13-10.22)	95.65 (89.24-98.80)	94.62 (87.90-98.23)	6.32 (2.35-13.24)
3	96.77 (90.86-99.33)	15.63 (9.02-24.46)	100.0 (96.27-100.0)	100.0 (96.23-100.0)	46.32 (36.02-56.85)	100.0 (96.07-100.0)	75.27 (65.24-83.63)	100.0 (96.34-100.0)	48.00 (37.90-58.22)	97.92 (92.68-99.75)	37.11 (27.52-47.52)	100.0 (96.07-100.0)	100.0 (96.11-100.0)	56.84 (46.28-66.97)
5	98.92 (94.15-99.97)	4.17 (1.15-10.33)	100.0 (96.27-100.0)	97.92 (92.68-99.75)	7.37 (3.01-14.59)	98.91 (94.09-99.97)	7.53 (3.08-14.90)	95.96 (89.98-98.89)	9.00 (4.20-16.40)	100.0 (96.23-100.0)	5.15 (1.69-11.62)	100.0 (96.07-100.0)	98.92 (94.15-99.97)	5.26 (1.73-11.86)
6A	97.85 (92.45-99.74)	80.21 (70.83-87.64)	97.94 (92.75-99.75)	89.58 (81.68-94.89)	65.26 (54.80-74.74)	96.74 (90.77-99.32)	78.49 (68.76-86.34)	94.95 (88.61-98.34)	95.00 (88.72-98.36)	95.83 (89.67-98.85)	92.78 (85.70-97.05)	97.83 (92.37-99.74)	95.70 (89.35-98.82)	81.05 (71.72-88.37)
7F	100.0 (96.11-100.0)	37.50 (27.82-47.97)	100.0 (96.27-100.0)	100.0 (96.23-100.0)	35.79 (26.21-46.28)	100.0 (96.07-100.0)	49.46 (38.93-60.03)	100.0 (96.34-100.0)	75.00 (65.34-83.12)	100.0 (96.23-100.0)	52.58 (42.18-62.81)	98.91 (94.09-99.97)	100.0 (96.11-100.0)	42.11 (32.04-52.67)
19A	100.0 (96.11-100.0)	44.79 (34.63-55.29)	100.0 (96.27-100.0)	100.0 (96.23-100.0)	78.95 (69.38-86.64)	100.0 (96.07-100.0)	88.17 (79.82-93.95)	100.0 (96.34-100.0)	92.00 (84.84-96.48)	100.0 (96.23-100.0)	79.38 (69.97-86.93)	100.0 (96.07-100.0)	100.0 (96.11-100.0)	78.95 (69.38-86.64)

Note: N: subjects included in PPS; CI*: 2-sided 95% CI for OPA antibody positive rate.

Table 12 OPA Antibody GMTs in Subjects of Each Age Group following Immunizations (PPS)

Serotypes	Post Primary Series									Post Complete Series				
	3 Months		2 Months	7-11 Months		12-23 Months		24-71 Months		3 Months		2 Months	7-11 Months	
	PCV13-TT N=93 GMT(CI*)	Prevenar® N=96 GMT(CI*)	PCV13-TT N=97 GMT(CI*)	PCV13-TT N=96 GMT(CI*)	Prevenar® N=95 GMT(CI*)	PCV13-TT N=92 GMT(CI*)	Prevenar® N=93 GMT(CI*)	PCV13-TT N=99 GMT(CI*)	Prevenar® N=100 GMT(CI*)	PCV13-TT N=96 GMT(CI*)	Prevenar® N=97 GMT(CI*)	PCV13-TT N=92 GMT(CI*)	PCV13-TT N=93 GMT(CI*)	Prevenar® N=95 GMT(CI*)
Common														
4	1227.93 (992.5-1519.2)	2291.32 (1947.8-2695.4)	1214.42 (940.3-1568.5)	1014.62 (866.1-1188.7)	1214.37 (1022.4-1442.4)	1756.58 (1426.1-2163.6)	1993.15 (1667.7-2382.2)	2710.14 (2176.9-3374.1)	1924.49 (1331.2-2782.2)	6182.37 (4931.4-7750.7)	6208.15 (4950.8-7784.8)	3440.10 (2690.0-4399.3)	1549.33 (1288.7-1862.7)	1465.72 (1253.1-1714.4)
6B	528.67 (329.58-848.02)	2928.36 (2233.9-3838.7)	811.17 (542.0-1214.1)	237.34 (142.61-395.00)	599.57 (373.97-961.29)	923.67 (611.9-1394.4)	1530.14 (921.8-2539.9)	2511.69 (1829.2-3448.8)	2511.16 (1760.5-3581.9)	2661.93 (1948.9-3635.9)	7564.42 (5345-10705)	1948.21 (1460.3-2599.2)	890.24 (599.4-1322.2)	1843.95 (1265.7-2686.4)
9V	1922.48 (1518.9-2433.2)	1974.62 (1612.0-2418.9)	2192.74 (1728.3-2781.9)	1425.78 (1153.3-1762.6)	1692.48 (1371.4-2088.7)	3219.64 (2417.8-4287.4)	2824.34 (2057.1-3877.8)	2174.68 (1710.1-2765.4)	1980.18 (1547.4-2534.1)	6184.75 (4870.3-7854.0)	5484.79 (4453.1-6755.5)	3719.77 (2889.7-4788.3)	2075.15 (1697.0-2537.6)	2264.80 (1886.3-2719.2)
14	4511.21 (3494.9-5823.1)	5594.48 (4188.4-7472.5)	3571.78 (2833.6-4502.3)	2538.79 (1929.1-3341.2)	3060.32 (2260.7-4142.7)	6373.82 (5041.8-8057.8)	7303.79 (5760.0-9261.3)	2534.19 (1586.7-4047.4)	3395.54 (2193.4-5256.5)	7686.96 (6160.6-9591.5)	6221.93 (4855.7-7972.5)	6173.16 (4922.7-7741.3)	3761.98 (3002.8-4713.1)	2883.34 (2359.5-3523.5)
18C	1356.26 (1094.5-1680.7)	3129.49 (2353.5-4161.3)	518.67 (417.13-644.92)	952.30 (748.0-1212.4)	1157.93 (908.2-1476.4)	3133.89 (2557.9-3839.5)	3971.64 (3197.8-4932.8)	3572.76 (2952.0-4324.1)	3330.72(2548.4-4353.1)	4173.73 (3269.4-5328.2)	5507.66 (4094.6-7408.5)	1117.88 (899.5-1389.3)	1491.46 (1230.2-1808.2)	1677.92 (1331.9-2146.1)
19F	652.57 (547.97-777.14)	540.56 (423.02-690.76)	769.17 (617.10-958.72)	518.08 (412.37-650.89)	240.27 (170.50-338.60)	816.50 (653.5-1020.2)	331.18 (230.91-474.99)	1133.78 (876.5-1466.6)	333.59 (233.90-475.75)	2359.26 (1898.8-2931.3)	815.68 (600.1-1108.8)	1966.07 (1496.8-2582.5)	751.55 (635.68-888.54)	258.60 (190.65-350.77)
23F	2090.78 (1452.4-3009.7)	5939.64 (4465.8-7899.8)	1072.95 (738.0-1560.0)	669.00 (444.5-1006.8)	1699.27 (1116.1-2587.2)	2069.47 (1616.3-2649.7)	3784.23 (2584.5-5540.9)	2025.10 (1465.3-2798.7)	3468.13 (2544.3-4727.4)	4943.66 (3817.5-6402.1)	16131.84 (11742-22163)	2529.55 (1959.0-3266.3)	1577.42 (1197.5-2077.9)	3607.17 (2428.0-5359.1)
Additional (vs. corresponding serotypes)														
1	62.13 (42.64-90.51)	2.00 (2.00-2.00)	92.51 (66.48-128.75)	56.40 (43.54-73.05)	2.24 (2.01-2.50)	42.36 (31.65-56.70)	2.23 (1.97-2.52)	8.16 (5.78-11.52)	2.07 (1.94-2.21)	321.14 (239.43-430.74)	2.28 (2.00-2.61)	158.59 (115.59-217.59)	87.89 (67.11-115.11)	2.34 (2.06-2.67)
3	511.70 (376.29-695.83)	2.80 (2.35-3.33)	575.94 (444.43-746.38)	316.46 (264.28-378.94)	6.62 (4.88-8.97)	361.20 (304.70-428.17)	14.09 (10.43-19.04)	121.39 (101.55-145.11)	9.67 (6.60-14.16)	678.98 (523.20-881.14)	5.03 (3.77-6.72)	586.01 (440.25-780.04)	431.54 (359.88-517.48)	8.12 (6.04-10.91)
5	450.24 (358.12-566.05)	2.24 (1.99-2.51)	411.73 (317.12-534.56)	115.18 (90.52-146.55)	2.43 (2.10-2.82)	192.91 (155.85-238.79)	2.80 (2.17-3.62)	84.80 (64.41-111.65)	2.51 (2.16-2.93)	1375.13 (1061.9-1780.8)	2.61 (2.07-3.29)	1027.83 (796.4-1326.6)	222.49 (173.71-284.98)	2.41 (2.02-2.87)
6A	1079.96 (792.9-1471.0)	275.54 (159.69-475.44)	1202.17 (895.0-1614.8)	442.24 (286.46-682.71)	95.37 (51.43-176.86)	1434.20 (1009.8-2037.0)	487.96 (251.04-948.50)	1737.99 (1185.4-2548.1)	970.59 (655.6-1437.0)	3254.75 (2221.0-4769.7)	1562.59 (972.9-2509.6)	2546.12 (1780.8-3640.3)	1234.03 (866.0-1758.5)	416.90(234.51-741.16)
7F	7741.10 (6383.8-9387.0)	12.76 (7.68-21.19)	2414.63 (1872.4-3113.9)	3589.60 (2955.9-4359.2)	16.04 (8.94-28.80)	5524.63 (4317.5-7069.2)	32.24 (17.72-58.68)	5886.86 (4802.3-7216.3)	171.55 (98.79-297.89)	7244.42 (6006.0-8738.3)	41.47 (22.27-77.21)	2616.75 (1938.6-3532.1)	4276.87 (3488.6-5243.3)	21.71 (12.04-39.14)
19A	777.70 (638.69-946.97)	11.50 (7.55-17.51)	659.70 (532.25-817.66)	692.99 (565.53-849.18)	57.76 (38.19-87.34)	1368.75 (1110.8-1686.6)	166.43 (110.60-250.45)	2070.66 (1638.8-2616.3)	303.83 (200.97-459.33)	5503.11 (4501.2-6728.1)	72.99 (46.46-114.65)	2546.03 (2030.4-3192.6)	1141.93 (928.0-1405.2)	71.60 (45.99-111.47)

Note: N: subjects included in PPS; CI*: 2-sided 95% CI for OPA antibody GMT.

14 STORAGE CONDITION
Transport and store refrigerated at 2°C to 8°C, protect from light.
DO NOT FREEZE. Discard if the vaccine is frozen.
Keep the product in places out of children's reach.

15 INCOMPATIBILITIES
This vaccine should not be mixed with other medicinal products considering that no compatibility studies have been conducted.

16 SHELF LIFE
Please use before the expiration date printed on the label or box.

17 PACKAGING AND REGISTRATION NUMBER
Box, 1 Pre-filled syringe @ 0.5 mL, Reg. No. DKLXXXXXXXXXXXX

Manufactured by :
PT Etana Biotechnologies Indonesia
Jakarta - Indonesia

HARUS DENGAN RESEP DOKTER

etana
Biotech

Final Artwork	
Item Name	Brochure PCV-13 back
Dimension	570 x200 mm
Item Code	N/A
CC no.	CC-EBI-OT-007-23
Font	See information on the side
Color	See information on the side
Material	HVS 60gsm
Revision	00

Font :
VALENINA® ____ Work Sans Extrabold 8pt
13-valent Pneumococcal Polysaccharide Conjugate Vaccine ____ Calibri bold 6.4pt
Others ____ Source Sans Pro 4.5pt

COLOR:
P Black C0; M0; Y0; K100
P2925C

DISETUJUI OLEH BPOM: 21/06/24

ID EREG100007VR12400033